ResearcherHokkaido UniversityNo recent work listed
Yuki Fujii
Matched on OpenAlex author ID A5103868989. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2021: 2 papers
Papers 2
- Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreat… Co-author DOI 10.1007/s10637-021-01118-1↗
- Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive panc… Co-author DOI 10.1186/s12885-020-07722-3↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Tatsuzo Mizukami · 2 shared papers, 2021 · strength 0.28
- Paper Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver meta… DOI 10.1007/s10637-021-01118-1↗
- Paper Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer c… DOI 10.1186/s12885-020-07722-3↗
- Fumihiko Matsuzawa · 2 shared papers, 2021 · strength 0.28
- Paper Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver meta… DOI 10.1007/s10637-021-01118-1↗
- Paper Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer c… DOI 10.1186/s12885-020-07722-3↗
- Hirofumi Kamachi · 2 shared papers, 2021 · strength 0.28
- Paper Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver meta… DOI 10.1007/s10637-021-01118-1↗
- Paper Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer c… DOI 10.1186/s12885-020-07722-3↗
- Akinobu Taketomi · 2 shared papers, 2021 · strength 0.28
- Paper Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver meta… DOI 10.1007/s10637-021-01118-1↗
- Paper Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer c… DOI 10.1186/s12885-020-07722-3↗
- Takahiro Einama · 1 shared paper, 2021 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.